search button

Detection of circulating vascular endothelial growth factor and matrix metalloproteinase‑9 in non‑small cell lung cancer using Luminex multiplex technology

  • Authors:
    • Ye Zhang
    • Jian‑Zhong Wu
    • Jun‑Ying Zhang
    • Jing Xue
    • Rong Ma
    • Hai‑Xia Cao
    • Ji‑Feng Feng

  • View Affiliations

  • Published online on: November 29, 2013     https://doi.org/10.3892/ol.2013.1718
  • Pages: 499-506
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

It has been previously reported that vascular endothelial growth factor (VEGF) and matrix metalloproteinase (MMP)‑9 are important for the occurrence and development of non‑small cell lung cancer (NSCLC). The present study was designed to detect the serum levels of VEGF and MMP‑9 in NSCLC, and to explore their diagnostic and prognostic values. A total of 543 cases were involved, of which 332 were NSCLC (272 cases in the pretreatment group and 60 cases in the postoperative group), 91 were patients with benign lung diseases and 120 were healthy controls. The serum levels of VEGF and MMP‑9 were determined by Luminex multiplex technology. The serum levels of VEGF and MMP‑9 were found to be significantly higher in the pretreatment group than those in the patients with benign lung diseases and healthy controls (VEGF, P<0.0001; MMP‑9, P<0.0001). Compared with the pretreatment group, the serum levels of VEGF and MMP‑9 in the postoperative group were significantly decreased (VEGF, P=0.005; MMP‑9, P=0.002), and the levels of VEGF and MMP‑9 in the pretreatment group of patients with stages III and IV were higher than those with stages I and II (VEGF, P<0.0001; MMP‑9, P=0.021). In addition, the levels of VEGF and MMP‑9 were found to closely correlate with lymph node metastasis (VEGF, P<0.0001; MMP‑9, P<0.0001) in the pretreatment group, while being independent of other clinicopathological parameters (P>0.05). Furthermore, a positive correlation was observed between the serum levels of VEGF and MMP‑9 (r=0.159; P=0.009). A receiver operating characteristic curve analysis showed that the diagnostic value of MMP‑9 was higher than that of VEGF in the pretreatment group. The log‑rank test indicated that the inoperable NSCLC patients with low levels of VEGF exhibited a significantly longer overall survival time than those with high VEGF levels (P<0.0001). Additionally, the serum levels of VEGF and lymph node metastasis were identified as independent prognostic factors of the inoperable NSCLC patients in a multivariate Cox regression analysis (P<0.05). These results indicated that VEGF and MMP‑9 may be potential biomarkers for the diagnosis and prognosis of NSCLC.
View Figures
View References

Related Articles

Journal Cover

2014-February
Volume 7 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.5
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 5.7
  • CiteScore Rank: Q2: #139/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.574
  • SCImago Journal Rank (SJR): 0.644
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Zhang Y, Wu JZ, Zhang JY, Xue J, Ma R, Cao HX and Feng JF: Detection of circulating vascular endothelial growth factor and matrix metalloproteinase‑9 in non‑small cell lung cancer using Luminex multiplex technology. Oncol Lett 7: 499-506, 2014.
APA
Zhang, Y., Wu, J., Zhang, J., Xue, J., Ma, R., Cao, H., & Feng, J. (2014). Detection of circulating vascular endothelial growth factor and matrix metalloproteinase‑9 in non‑small cell lung cancer using Luminex multiplex technology. Oncology Letters, 7, 499-506. https://doi.org/10.3892/ol.2013.1718
MLA
Zhang, Y., Wu, J., Zhang, J., Xue, J., Ma, R., Cao, H., Feng, J."Detection of circulating vascular endothelial growth factor and matrix metalloproteinase‑9 in non‑small cell lung cancer using Luminex multiplex technology". Oncology Letters 7.2 (2014): 499-506.
Chicago
Zhang, Y., Wu, J., Zhang, J., Xue, J., Ma, R., Cao, H., Feng, J."Detection of circulating vascular endothelial growth factor and matrix metalloproteinase‑9 in non‑small cell lung cancer using Luminex multiplex technology". Oncology Letters 7, no. 2 (2014): 499-506. https://doi.org/10.3892/ol.2013.1718